LDLyubov A. Davydova

Lyubov A. Davydova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lyubov A. Davydova has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non‑invasive monitoring and prognostic indicators in critical conditions: from hemodynamics to metabolism (systematic review)

    by E. Yu. Bersenev, T. A. Lapina, O. V. Kurilova, E. O. Sello, L. A. Davydova, S. V. Tsarenko, K. S. Gorbunov, Е. Ю. Берсенев, Т. А. Лапина, О. В. Курилова, et al.

    Non‑invasive monitoring and prognostic indicators in critical conditions: from hemodynamics to metabolism (systematic review) | Bersenev | Extreme Medicine Неинвазивный мониторинг и прогностические индикаторы в критических состояниях: от гемодинамики до метаболизма (систематический обзор) | Берсенев | Экстремальная биомедицина

  • Open Access

    Susceptibility of Klebsiella pneumoniae Clinical Isolates in Biofilms to Antibiotics and Assessment of Secondary Drug Effects

    by Daria A. Burmistrova, Nadezhda A. Gultiaeva, Kseniya V. Danilova, Ivan N. Kravtsov, Andrey I. Solovyev, Anastasia V. Kartashova, Olga L. Voronina, Marina S. Kunda, Natalia N. Ryzhova, Ekaterina I. Ermolova, et al.

    Biofilms pose a significant challenge to antimicrobial therapy. Bacteria in biofilms differ from planktonic counterpart in their altered metabolism, collective behavior, protective role of extracellular matrix and diversified microbial subpopulations. These attributions significantly influence bioavailability and activity of antibiotics. The presence of bacterial aggregates during acute infections expands the problem to many other conditions previously not discussed in the biofilm context. Klebsiella pneumoniae is a leading cause of life-threatening hospital-acquired infections and is included in the WHO Bacterial Priority Pathogens List due to increasing antimicrobial resistance. The combination of antimicrobial resistance and the ability to form biofilms severely limits the efficacy of antibiotic treatments. In this study, we investigated the in vitro susceptibility of mature biofilms to 13 antimicrobials of K. pneumoniae clinical isolates from a single hospital. The resistance profiles of the local clinical isolates were consistent with the global epidemiology of K. pneumoniae . Minimal biofilm eradication concentrations (MBEC) for mature biofilms were defined with two assays (biomass and metabolic activity measurements) and brought into relation with susceptibility breakpoints and plasma ( C max ). Colistin sulfate, tigecycline, cephalosporins and combination of imipenem with cilastatin were the most potent biomass eradicators, while suppression of metabolic activity was barely reachable. Moreover, we observed a notable increase in metabolic activity upon exposure to sub-MBEC concentrations of antibiotics. Finally, our data broach a subject of antibiotic prioritization with respect to biofilm tolerance. IMPORTANCE: This study addresses the critical gap between standard antibiotic susceptibility testing and the tolerance of biofilm and microbial aggregates during infections caused by K. pneumoniae. By systematically evaluating mature biofilms from a significant number of clinical isolates, we demonstrate that colistin and tigecycline show potent activity against both biofilm biomass and metabolic activity, whereas cephalosporins primarily reduce biomass without effectively suppressing bacterial metabolism, and other drugs have only weak effects on biofilms at clinically achievable concentrations. Furthermore, the alarming observation that sub-inhibitory biofilm eradication concentration (sub-MBEC) of antibiotic can paradoxically increase the metabolic activity of biofilms highlights a potential risk factor for therapy failure and resistance development. Our findings contribute to the necessary evidence base for prioritizing existing antibiotics in the limited armamentarium against biofilm-forming K. pneumoniae .

  • Open Access

    Cardiac Arrest in Adult Patients. Clinical Guidelines

    by A. N. Kuzovlev, V. A. Boboshko, E. A. Boeva, E. V. Grigoriev, P. A. Davydov, L. A. Davydova, L. I. Dezhurny, I. B. Zabolotskikh, A. A. Kolodkin, A. A. Krylov, et al.

    These guidelines were developed by a team of leading experts and representatives of the Federation of Anesthesiologists and Reanimatologists, the Russian Society of Emergency Medicine, the National Resuscitation Council and the Russian Society of First Aid.The guidelines provide a comprehensive framework for resuscitating adult patients with circulatory arrest. They cover: standardized terminology related to cardiac arrest; etiology and pathogenesis of cardiac arrest; epidemiology of both out-of-hospital and in-hospital cardiac arrest; diagnostic principles; algorithms for basic life support, including the use of automated external defibrillators; advanced cardiac life support protocols; special considerations for extracorporeal life support (ECLS); resuscitation procedures in catheterization laboratories, for cardiac surgery patients, and during labor; legal aspects of justified withdrawal (termination) from resuscitation efforts; quality indicators in emergency care.The guidelines also feature illustrated step-by-step algorithms for resuscitation procedures. The document includes 14 appendices and 232 references.